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Abstract
Despite advances in radical surgery and chemotherapy delivery, ovarian cancer is the most lethal gynecologic malignancy.
Standard therapy includes treatment with platinum-based combination chemotherapies yet there is no biomarker model to
predict their responses to these agents. We here have developed and independently tested our multi-gene molecular
predictors for forecasting patients’ responses to individual drugs on a cohort of 55 ovarian cancer patients. To
independently validate these molecular predictors, we performed microarray profiling on FFPE tumor samples of 55 ovarian
cancer patients (UVA-55) treated with platinum-based adjuvant chemotherapy. Genome-wide chemosensitivity biomarkers
were initially discovered from the in vitro drug activities and genomic expression data for carboplatin and paclitaxel,
respectively. Multivariate predictors were trained with the cell line data and then evaluated with a historical patient cohort.
For the UVA-55 cohort, the carboplatin, taxol, and combination predictors significantly stratified responder patients and
non-responder patients (p=0.019, 0.04, 0.014) with sensitivity=91%, 96%, 93 and NPV=57%, 67%, 67% in pathologic
clinical response. The combination predictor also demonstrated a significant survival difference between predicted
responders and non-responders with a median survival of 55.4 months vs. 32.1 months. Thus, COXEN single- and
combination-drug predictors successfully stratified platinum resistance and taxane response in an independent cohort of
ovarian cancer patients based on their FFPE tumor samples.
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Introduction
Epithelial ovarian cancer (EOC) is responsible for more deaths of
women in the United States than any other gynecologic malignancy
[1]. Despite attempts to implement effective early detection, the
majority of women continue to present with advanced stage disease.
While over 70% of patients will achieve a complete response with
primary cytoreductive surgery and platinum-based chemotherapy,
nearly 75% will recur in an average of 21 months [2]. In the
recurrent setting, ovarian cancer is rarely cured, in large part due to
progressive chemoresistance. For this reason, the 5-year overall
survival for EOC remains around 20% [3].
Primary surgery with maximal cytoreduction followed by
adjuvant chemotherapy with a platinum-taxane doublet is the
initial treatment of choice in advanced ovarian cancer. Despite
prospective data demonstrating a more favorable outcome for
patients who had complete surgical removal of metastatic disease,
the majority of patients continue to experience recurrence,
especially when a patient’s tumor is platinum-resistant [2].
Therefore, it is well recognized that surgery alone cannot
overcome disease progression in ovarian cancer, and the
phenotype of ‘‘platinum resistance’’ is thus unarguably one of
the most important clinical determinates [4]. About 30% of
patients whose tumors are platinum-resistant will generally either
progress during primary therapy or shortly thereafter—a grim
reminder of the limits of current ovarian cancer care and the need
for improved understanding of tumor biology and therapeutics
over surgical success. Moreover, the setting of platinum resistance
is a clinical conundrum: even though multiple FDA-approved
chemotherapy agents are available for treatment of recurrent
ovarian cancer, all have similar clinical response rates and thus
there is no preferred standard second-line chemotherapy to offer
these patients. Furthermore, no diagnostic tool or guidance is
available to provide individualized care for the heterogeneous
group of patients who comprise current clinical practice.
Recent efforts to improve survival after primary therapy have
focused on novel combinations of standard chemotherapies and
the use of targeted agents as seen in two recent Gynecologic
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alternative approach has been to focus on determining the sensitivity
of an individual patient’s tumor to standard medicines with a variety
of drug sensitivity and resistance tests [6,7]. The underlying premise
of this approach is that by matching a given chemotherapy to an
individual tumor with demonstrated sensitivity, physicians hope to
achieve higher response rates, more durable tumor-free intervals,
and fewer side effects compared to the standard of care (e.g. empiric
choice of agents for individual patients). Unfortunately, when
examined in a randomized trial, these chemotherapy sensitivity
and resistance tests did not improve progression free or overall
survival compared to the standard of care [8].
Molecular prediction signatures have also been developed using
retrospective data sets of ovarian cancer patients treated with
platinum-based chemotherapy [9]. However, these current
methods for assessing chemosensitivity have been of limited use
due to several shortcomings. First, these tests and signatures have
been developed only based on patient data restricted to current
drug combinations. Consequently, these patient-based predictors
were unable to differentiate tumors with heterogeneous responses
to various single agents. Also, previous molecular prediction
techniques were validated based on highly-controlled patient
cohorts in clinical trials that collected fresh frozen tissues. These
techniques often fail to consistently perform well with lower-
quality patient samples such as FFPE tissues that are customarily
collected in clinical practice. Because of these limitations,
molecular prediction signatures have been neither validated
against a vast amount of archived FFPE patient samples, nor
readily applied in diverse clinical settings.
The co-expression extrapolation (COXEN) method, an in vitro
cell-line-based multi-gene prediction technique, has been demon-
strated previously with its high potential to forecast chemother-
apeutic outcomes of cancer patients [10]. Several subsequent
studies have provided promising results in different cancer sites
including breast, ovarian, and bladder cancer [11,12,13].
COXEN predictors can x initially be developed independently
from patient tumors that are often treated with various drug
combinations, by using a single chemotherapeutic agent’s in vitro
cancer cell-line activities associated with genome-wide expression
data. The so-called COXEN biomarkers that are concordantly
regulated between the cell lines and in vivo patient tumors are then
further identified from these initial biomarkers to link in vitro cell
line chemosensitivity to a patient’s chemotherapeutic response,
overcoming the differences of the tumor microenvironment and
drug metabolism [13].
Since nearly all EOC tumors (.70%) will be platinum-sensitive
during primary therapy, only the identification of patients sensitive
to platinum agents may not provide high clinical utility. A more
clinically useful scenario would be the reliable identification of
patients for whom standard therapies will fail (i.e. the small
proportion (less than 30%) of platinum-resistant patients). These
patients could then be guided to alternative chemotherapy agents
and treatment options, potentially avoiding unnecessary toxicity.
We undertook this study in an effort to validate the COXEN
prediction assays for their clinical utility, using an independent
ovarian cancer patient cohort with archived FFPE tumor samples.
Our hypothesis was that COXEN could reliably predict platinum
resistance in a series of advanced epithelial ovarian cancer patients.
Materials and Methods
Cell line drug activity and microarray data
In vitro drug activity and microarray data of the NCI-60 cancer
cell panel were previously described elsewhere [10]. In brief,
publicly-available drug sensitivity data, expressed in terms of 50%
growth inhibition (GI50) for the NCI-60 were obtained from the
NCI DTP web site (http://dtp.nci.nih.gov). NCI-60 expression
profiling data on HG-U133A GeneChipH arrays (Affymetrix,
Santa Clara, CA) were from a public domain at the National
Cancer Institute (http://discover.nci.nih.gov). The second cell line
set, Peter-18, was based on six ovarian cancer cell lines with in vitro
drug activity for carboplatin [14]. These cell lines were originally
derived from six ovarian carcinoma (papillary serous adenocarci-
noma) patients. These cell lines were then characterized as either
carboplatin sensitive (n=3) or resistant (n=3) based on their in
vitro cell-line drug sensitivity after treatment. Specifically, these cell
lines were experimented to evaluate the cytotoxic index (% kill) of
,350 cells seeded into 60-well microtiter plates, grown for 24 hrs
and treated with different concentrations of carboplatin, compared
to untreated controls at 48 hrs after treatment [14]. Three
replicated cultures of each cell line were then subject to genome-
wide expression profiling using Affymetrix HG-U95A GeneChipH
arrays. These sets are summarized in Table 1.
Historical patient sets for predictor development and
evaluation
Microarray gene expression data from frozen tissue samples
obtained at the time of primary cytoreductive surgery from two
previously-published human ovarian cancer cohorts were also
used for the development and independent evaluation of our
molecular predictors. The first cohort of 185 primary ovarian
tumors treated with adjuvant chemotherapy was originally
obtained for identifying prognostic molecular signatures of survival
[15]. We used the subset of 167 patients with platinum-based
chemotherapeutic response information for our predictor devel-
opment. These patients comprised 112 (67%) complete response
(CR), 41 (25%) partial response (PR), and 14 (8%) progress of
disease (PD). The second set (Dressman-119) of 119 ovarian
cancer patients from the Duke University and H. Lee Moffitt
Cancer Center also received platinum-based adjuvant chemother-
apy [9]. Of 119, 85 (71%) patients had a complete response
whereas 34 (29%) patients showed an incomplete response (IR) to
the chemotherapy. Expression profiling data of the frozen-tissue
tumor samples from both sets were available with Affymetrix HG-
U133A GeneChipH arrays.
Independent cohort of patients and FFPE tumor samples
After an Institutional Review Board approval, the UVA Cancer
Registry was queried to identify stage III–IV epithelial ovarian
cancer patients treated between 1995–2004 whose follow-up
information was available for at least five years or were deceased.
For inclusion in the validation cohort, patients must have had a
primary surgery followed by platinum-based chemotherapy. Sixty-
five patients were identified both from the UVA Cancer Registry
and Biorepository Tissue Research Facility (BTRF). Patients were
excluded if they lacked adequate follow-up clinical data for review.
These cases were also examined whether they had adequate
archived pathologic material for molecular analysis. Ten patients
were excluded from these, leaving 55 patients available for the
validation of COXEN predictors (UVA-55). Formalin-fixed
paraffin embedded (FFPE) tissue blocks were obtained for each
patient in the validation cohort. These blocks were reviewed by a
pathologist to ensure an adequate tumor was present for analysis.
The corresponding histologic sections were examined by a
pathologist and areas of tissue with tumor cell percentages
.70% were selected. Only blocks that contained .2m m o f
tissue thickness were used to obtain tumor tissue of the block with
3 mm biopsy punches for subsequent microarray analysis.
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rized in Table 2. All patients received a primary surgical effort by
a board-certified gynecologic oncologist and a gynecologic
pathologist reviewed all pathology. Adjuvant chemotherapy
consisted of platinum (carboplatin or cisplatin) either alone
(n=2) or in combination with a taxane (n=51, paclitaxel or
docetaxel) or cyclophosphamide (n=2). Response assessment and
surveillance schedules followed accepted clinical practice. The
median age in this cohort was 62 (range 38–65) and the majority
were stage III cancers (91%) of serous histology (85%). The
median progression-free survival was 13 months (95% CI 10–16)
and the median overall survival for the cohort was 50 months
(95% CI 32–68). All research involving human participants have
been approved by the institutional review board at the University
of Virginia. Witten informed consents were obtained from all
participants involved in the study.
Microarray Profiling on FFPE Tumor Samples
Gene expression profiling from the two 3 mm core punches of
FFPE tumor tissue blocks containing .70% tumor cells were
performed by Almac Diagnostics, Inc. (Durham, NC) based on its
standard protocol. In particular, RNA extraction and amplifica-
tion were performed with the NuGen WT-Ovation
TM FFPE RNA
Amplification kit which is specialized to overcome the cross-linked
and fragmented RNAs in FFPE samples (NuGen, Inc., San Carlos,
CA). Data normalization and quality control assessment of the
hybridization results were performed with the RMA Bioconductor
package (http://www.bioconductor.org).
Statistical Methods
The procedures for our predictor training and test are
summarized in Figure 1. In brief, COXEN predictors for
paclitaxel and carboplatin were first derived from in vitro drug
sensitivity and microarray data [10]. Candidate biomarkers that
were highly associated with carboplatin and paclitaxel sensitivity
were identified from the Peter-18 and NCI-60 microarray data,
respectively. That is, the 10–35% most and least sensitive cell lines
based on GI50 (growth-inhibition 50%) or cell kill percent values
were correlated with genome-wide expression data to identify
initial chemosensitivity biomarkers for each drug. These initial
biomarkers were filtered with FFPE-robust probe sets (about 55%
of all probe sets) which were previously derived from our in-house
dataset comprising .27 paired frozen and FFPE tumor samples
(data not shown). These FFPE-robust chemosensitivity biomarkers
Table 1. Cell and patient data sets used for COXEN Predictor Training and Testing.
Name Sample type
Array Platform
(# of probes)
Responder
(sensitive)
Non-responder
(resistant) Drugs
(Training)
NCI-60 Cell lines HG-U133A
(22,215)
10 22 Taxol
Peter-18
(GSE1926)
Cell lines HG-U95
(9,530)
9 9 Carboplatin
Bonome-185 Human
patients
HG-U133A
(22,283)
112 55 Carboplatin, Taxol, Cisplatin,
Cytoxan
(Testing)
Dressman-119 Human
patients
HG-U133A
(22,215)
85 34 Platinum-based chemotherapy
UVA-55 Human
patients
HG-U133+2
(54,675)
`32 23 Carboplatin Taxol
NCI-60 and Peter-18 cell-line data sets were used to discover chemosensitivity biomarkers and to train multivariate statistical prediction models for paclitaxel and
carboplatin, respectively. Bonome-185 set was used to select the biomarkers with the consistent directions of differential expression. Dressman-119 set was used to
independently evaluate the trained predictors and to derive the optimal cutoff value of each predictor. UVA-55 set was purely used to test the predictability of the
COXEN predictors in a prospective manner.
doi:10.1371/journal.pone.0030550.t001
Table 2. Clinical Characteristics of the UVA-55 Cohort.
Characteristic N (%)
Patients 55
Median Age (range) 62 (38–65)
Ethnicity
White 51 (93%)
Black 4 (7%)
Stage
III 50 (91%)
IV 5 (9%)
Histology
Serous 47 (85%)
Clear Cell 5 (9%)
Other 3 (6%)
Surgical Outcome
Optimal (,1 cm) 30 (55%)
Sub-optimal ($1 cm) 25 (45%)
Response to Initial Therapy
CR 32 (58%)
PR, PD 23 (42%)
Recurrences 48 (87%)
Deaths 36 (65%)
Survival (months)
Median PFS 13 (95% CI, 10–16)
Median OS 50 (95% CI, 32–68)
CR=Complete Response, PR=Partial Response, PD=Progressive Disease,
PFS=Progression Free Survival, OS=Overall Survival, CI=Confidence Interval.
doi:10.1371/journal.pone.0030550.t002
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represents the degree of concordance of expression regulation
between the NCI-60 cell lines and human ovarian cancer patients.
In brief, the mathematical derivation of COXEN coefficient is
based on the so-called ‘‘correlation of correlations,’’ which first
calculates the expression correlations within each set on the
identical set of genes of interest for both sets and then evaluates
gene-by-gene correlation between the two correlation matrices of
the two sets. This kind of 2nd-order correlation has proven useful
to investigate various gene networks to identify concordant ones
across different data sets by us and others [16,17,18]. More
detailed description of the COXEN algorithm has been desctibed
elsewhere [10,11]. Expression patterns of these NCI-60-based
chemosensitivity biomarkers were further compared to those in a
cohort of 185 human ovarian cancer patients, and were excluded
if their expression changes were inconsistent between the two sets.
Some relevant issues on these filtering steps are discussed later.
Genes with significant COXEN coefficients were then used for
our drug-specific prediction modeling using a double cross-
validated linear discriminant analysis (LDA) on the Peter-18 cell
lines for carboplatin and the NCI-60 cell lines for paclitaxel,
respectively as described elsewhere [19]. The resulting COXEN
predictors were simultaneously applied to the two independent
patient cohorts of Dressman-119 frozen and UVA-55 FFPE tumor
samples. Assuming their independence, combined prediction
scores from the two individual drug predictors were simply
calculated to generate a combination chemotherapy (CT)
predictor.
Performance of these predictors was first evaluated by testing a
significant difference in the COXEN scores between the CR and
PR patient groups using a non-parametric Wilcoxon rank-sum
test. We also performed an ROC (receiver operator characteristics)
analysis both to evaluate their overall predictability by the area
under the curve (AUC) and to define optimal cutoff values for high
clinical utility. The optimal cutoff values for the COXEN
predictors were first determined by maximizing the Youden index
(=sensitivity+specificity-1) on the ROC curves. At this Youden
cutoff value, the sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) for stratifying clinical
responders (pCRs) from non-responders were then derived
independently on our validation patient sets [20]. However, if
these mathematically-derived cutoff values could not provide a
high clinical utility, i.e., a low NPV, we then found alternative
cutoff values by maximizing NPV (see Supplementary Methods in
Text S1 for more details).
Results
COXEN Predictors of Carboplatin and Paclitaxel
We identified the final FFPE-robust 251 and 125 biomarkers for
the training of carboplatin and paclitaxel predictors, respectively,
on the NCI-60 and Peter-18 cell line panels. For each set of
biomarkers, hierarchical clustering and biological pathway
analyses were performed, the latter by Ingenuity Pathway Analysis
(IPA, Ingenuity, Inc., Redwood City, CA; Supplementary
Figure S1). Distinctly, carboplatin biomarkers were from cell
cycle/tissue disorder, hematological system development, organ-
ismal functions, and cellular growth/proliferation associated
network functions. Biomarkers from these networks were, in fact,
found to be closely clustered in the clustering heatmap analysis
(Figure 2; Supplementary Table S1). In particular, the
responders (red) and nonresponders (green) were found to be
generally clustered together even in this unsupervised clustering
analysis. Paclitaxel biomarkers were also found to be from cell
death, DNA replication, recombination, and repair networks
(Supplementary Table S1; Supplementary Figure S1B, C).
These biomarkers of each drug were used to develop COXEN
multivariate prediction models.
Validation on independent patient cohorts
The performance of these multi-gene predictors was first
independently examined on the frozen-tissue-based Dressman-
119 cohort. We found the COXEN scores of both carboplatin and
paclitaxel predictors for responder patients were significantly
higher than those of non-responder patients in this set (Wilcoxon
rank-sum test P=0.036 for carboplatin and P=0.035 for
paclitaxel). The combined prediction scores for the two drugs
also significantly stratified responder patients from the non-
responders in this cohort (Wilcoxon rank-sum test P=0.038)
(Figure 3A, B, and C).
The unaltered COXEN predictors were then used for
predicting chemotherapeutic responses of the FFPE tissue-based
UVA-55 cohort for both single and combination agents. We again
found the predicted sensitivity scores of each of carboplatin and
paclitaxel of the responders were significantly higher than those of
Figure 1. Schematic Summary of COXEN Predictor Develop-
ment and Test.
doi:10.1371/journal.pone.0030550.g001
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test P=0.019 for carboplatin and P=0.041 for paclitaxel). The
combination-drug predictor also provided a significant difference
between responders and non-responders (P=0.014) in the UVA-
55 cohort (Figure 3D, E, and F). These predictors provided high
stratification capability between responders and non-responders in
the ROC analysis: combination predictor AUC 0.604 [95% CI:
0.483–0.723] and 0.703 [0.549–0.856] with Wilcoxon P=0.038
and 0.009 on the two sets, respectively, which well demonstrated
the significance of their overall predictability (Table 3).
Survival benefit of COXEN predictors
As described above, these predictors showed statistical signifi-
cance in their overall predictability. However, one still needs to
define a fixed cutoff value for each predictor in order to evaluate
its clinical benefit a priori, thus defining responder vs. nonresponder
Figure 2. COXEN Biomarkers and Gene Networks for Carboplatin. Clustering heatmap analysis with major gene networks with x-axis
responder (red) and non-responder (green) patients and y-axis Immunological disease/cell death entwork (red), Cell cycle/Connective tissue
disorders/Inflammator disease network (green), Cellular movement/Hematological system/Immune cell trafficking network (yellow), and Free radical
scavenging/cellular movement/cancer/cellular growth and proliferation network (blue).
doi:10.1371/journal.pone.0030550.g002
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mathematical cutoff points of these predictors by maximizing the
Youden index (=specificity+sensitivity-1) on the Dressman-119
cohort cohort (Supplementary Table S2). These predictors
with the Youden cutoff values (for stratifying pathologic clinical
response to chemotherapy) provided a significant survival
difference between predicted responder and non-responder
groups. Only overall survival time was available both for
Dressman-119 and UVA-55 cohorts so we used this survival
outcome endpoint to directly compare predicted survival benefit
on the two cohorts. Overall survival time longer than 5 years was
censored to avoid mathematical artifacts from a few patients’
outlying survival times (e.g. .10 years) in our survival analysis.
Death beyond this time period (after chemotherapy) may not be
directly relevant to the chemotherapeutic response. The clinical
characteristics (e.g. surgical outcome, chemotherapy agents) of
patients with .5 years of survival were not significantly different
from the remaining cohort (data not shown). For the Dressman-
119 cohort, we found the combination-drug COXEN predictor
provided a highly significant survival difference by a Kaplan-
Meier survival analysis (log-rank test P=0.0002; Figure 4A). The
median survival times were 77.8 and 22.3 months between
predicted responder and non-responder groups in the cohort. For
the UVA-55 cohort, the identical combination-drug predictor also
similarly provided a survival difference between the two groups
(log-rank test P=0.094; Figure 4B); statistical significance was
only marginally significant, likely due to a relatively small sample
size in this cohort. The median survival times were 55.4 and 32.2
months between predicted responders and non-responders among
these UVA-55 patients.
Clinical Utility of COXEN Predictors
Over ,75% patients with ovarian cancer respond to the initial
platinum-based chemotherapy. This leads to an important
requirement for platinum-based chemotherapy biomarkers in
ovarian cancer. First, it is impractical in treating patients to use the
above mathematically-derived cutoff value, which considers the
same weights both for false negatives and false positives. The
number of false negatives, i.e. incorrectly predicted responders, is
still not a small number at such a cutoff value (,15% of all
responders), which cannot be ethically used in clinical practice.
Therefore, in order to examine clinical utility of our biomarkers,
we defined the cutoff values by maximizing negative predictive
value (NPV) on Dressman-119. We then independently evaluated
these cutoffs on our UVA-55 cohort in a prospective manner,
which showed significant improvement of NPV to 67% (10/15),
75% (6/8), and 71% (5/7) for the carboplatin, paclitaxel, and
combination predictors, respectively (Table 3). We also found
that these provided very high sensitivity 91%, 96%, and 93% with
the three predictors. Therefore, using these cutoff values, one
Figure 3. Evaluation and Validation result on ovarian patients. Figures 3A, 3B, and 3C are evaluation resulton the Dressman-119 cohort; (A)
the distribution of COXEN scores for Carboplatin; (B) COXEN scores for paclitaxel; (C) COXEN scores for the drug combination of Carboplatin and
Paclitaxel. Figures 3D, 3E, and 3F are validation result on the UVA-55 cohort for Carboplatin, Paclitaxel, and for the drug combination of Carboplatin
and Paclitaxel, respectively. Coxen scores of responder (black) and non-responder(gray). P-values calculated by Wilcoxon rank sum test.
doi:10.1371/journal.pone.0030550.g003
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primary platinum-based chemotherapy both on Dressman-119
and UVA-55 cohorts, maintaining .93% sensitivity (Table 3;
Supplementary Figure S2).
We also investigated whether the chemotherapeutic response
prediction could be improved by using other clinical parameters
such as age, tumor stage, optimal debulking status, or race by a
multivariate logistic regression analysis. We found that only the
COXEN molecular predictor was a significant factor and other
clinical variables were not significantly predictive of chemotherapy
responses (Supplementary Table S3). Finally, we calculated the
odds ratio of platinum-based chemotherapy response between
predicted responders and predicted non-responders. The odds
ratios were 7.16, 95% CI [1.315–38.912] for the Dressman-119
cohort and 4.51, 95% CI [1.013–20.096] for the UVA-55 cohort
(Supplementary Figure S3). Therefore, the odds of chemotherapy
response was .4.5 times higher for the predicted responder
patients of the two diverse cohorts.
Table 3. Prediction performance of COXEN predictors.
Compound
Data
(Res, Nonres)
AUC
[95% CI]
(P-value) Sensitivity (Specificity) PPV NPV
Carboplatin Dressman
(85, 34)
0.606
[0.483–0.730]
(p=0.036)
0.941(80/85)
(0.891–0.991)
0.294 (10/34)
(0.141–0.447)
0.769(80/104)
(0.688–0.850)
0.667 (10/15)
(0.428–0.905)
UVA-55
(32, 23)
0.617
[0.464–0.769]
(p=0.072)
0.906 (29/32)
(0.805–1)
0.174 (4/23)
(0.019–0.328)
0.604 (29/48)
(0.465–0.743)
0.571 (4/7)
(0.205–0.938)
Taxol Dressman
(85, 34)
0.595
[0.478–0.712]
(p=0.053)
0.976 (83/85)
(0.944–1)
0.176 (6/34)
(0.048–0.304)
0.747 (83/111)
(0.667–0.828)
0.75 (6/8)
(0.450–1)
UVA-55
(28, 23)
0.642
[0.488–0.797]
(p=0.041)
0.964 (27/28)
(0.900–1)
0.087 (3/23)
(0.422–0.702)
0.562 (27/48)
(0.422–0.703)
0.667 (2/3)
(0.133–1)
Carbo/Tax Dressman
(85, 34)
0.604
[0.483–0.723]
(p=0.038)
0.976 (83/85)
(0.944–1)
0.147 (5/34)
(0.028–0.266)
0.741 (83/112)
(0.660–0.822)
0.714 (5/7)
(0.380–1)
UVA-55
(28, 23)
0.703
[0.549–0.856]
(p=0.009)
0.928 (26/28)
(0.833–1)
0.174 (4/23)
(0.019–0.329)
0.577 (26/45)
(0.433–0.722)
0.667 (4/6)
(0.289–1)
The overall predictability (AUC) of identical COXEN predictors are summarized on the Dressman-119 and UVA-55 cohorts by AUC values with their 95% CIs and p-values.
Cutoff values of COXEN predictors were derived by maximizing NPVs on the Dressman-119 cohort. Sensitivity, specificity, PPV, and NPV values were evaluated on both
Dresseman-119 and independent UVA-55 cohort.
doi:10.1371/journal.pone.0030550.t003
Figure 4. Overall Survival Difference between COXEN Predicted Responders vs. Non-Responders. (A) Kaplan Meier survival plot of
Dressman-119 cohort. (B) Kaplan Meier survival plot of UVA-55 cohort. The survival curves of patients predicted to be responders (Red) and non-
responders (Green) showed significant differences between COXEN predicted responders and non-responders with median survival times 77.8 and
22.3 months for the Dressman-119 cohort and 55.4 and 32.2 months for the UVA-55 cohort between the two groups. P-values were calculated by
Log-rank test.
doi:10.1371/journal.pone.0030550.g004
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We have developed and independently validated multi-gene
predictors for the two primary chemotherapeutic agents in ovarian
cancer—carboplatin and paclitaxel. These molecular predictors
significantly and consistently stratified the responder patients from
the non-responders using two independent and distinctive patient
cohorts in their clinical settings and tumor sample types. In
particular, the identical predictors (and their pre-defined cutoff
values) provided consistent prediction capability in both settings.
We believe that this is quite encouraging, especially since they
could be successfully applied with a high prediction performance
both on the frozen tissue and the archived FFPE patient samples
which may enable us to utilize these tests for a much wider
retrospective validation and in clinical settings.
At the clinical optimal cutoff points (maximizing NPV), these
predictors could identify .70% of non-responders to primary
platinum-based chemotherapy who may be guided to choose
different therapeutic options, potentially avoiding unnecessary
toxicity. While this may provide a clinical utility in the primary
chemotherapy to pre-select a small number of non-responder
patients, it can be more useful in the second-line or subsequent
chemotherapy selection for which the proportion of non-
responders is significantly higher. However, we are well aware
that these results may still not provide sufficient clinical utility to be
used in the primary treatment setting. Instead, these single-drug
predictors would be highly useful for patients receiving second-line
and subsequent chemotherapeutic decisions for whom chemo-
therapeutic responses are much more heterogeneous (and response
rates lower for each agent).
COXEN predictors showed statistically significant predictability
simultaneously on the Dressman-119 and UVA-55 cohorts which
were quite heterogeneous in their clinical settings and tumor tissue
types, i.e. fresh frozen tumor vs. paraffin embedded. We also
believe these were encouraging results. COXEN is best thought of
as a screening tool for chemotherapy response, so we believe
.90% sensitivity with ,70% NPV seen in our independent
testing demonstrates its general clinical utility.
Several additional points are worth mentioning. The cell lines
for our in vitro ovarian cancer training were serous adenocarcino-
mas. The Dressman-119 cases were also reported to be serous
adenocarcinomas. All patient-derived tumors were advanced stage
(III–IV). We found no difference in the predictor performance
with stratification by histology (data not shown). The COXEN
approach is based on multiple filtering steps for discovering the
most predictive biomarkers for an individual patients’ therapeutic
response. Its initial discovery starts from in vitro drug activity data
of cancer cell lines to identify gene expression biomarkers only
relevant to single drug activities, which is infeasible from human
patient data since patient data are often confounded with their
prognostic and other treatment factors. On the other hand, the
majority of biomarkers initially discovered from cell line data are
not similarly regulated and functioning in vivo. We believe this is
why direct attempt to use the molecular observations from cell line
data has been difficult to be translated to the clinical setting. We
employed several biomarker filtering steps to avoid such pitfalls.
One of our initial steps is to confirm whether candidate genes’
expression changes observed between the sensitive and resistant
cell lines (to the drug of interest) have been consistently shown in
patients treated with the drug. For this we used a training patient
set, Bonome-185, which is completely independent of our test sets.
To obtain our final biomarkers, we used other filtering steps
including the COXEN step which examines the concordant
expression regulation networks among the chosen biomarkers.
Note that all these filtering steps were performed independent of
and prior to applying to our test sets.
Linear discriminant analysis (LDA) is one of the widely-used
multivariate classification techniques in statistics. We have used
other techniques such as SVM and logistic regression (data not
shown), and found that the prediction performance was generally
similar for the same data set. We here used LDA, taking advantage
of its elegant prediction and inference capability, such as easy
expansion to multi-classes and posterior probabilities of member-
ship conditional on the observed data. Mechanisms of action and
patient responses to carboplatin and taxol are believed to be
independent, which is one of the reasons why this combination
chemotherapy is widely used in ovarian cancer. However, there
often exists a certain degree of correlation in patient response
between different drugs. In our current study we assumed their
independence in order to statistically derive the combination
prediction scores from the two drugs’ individual prediction scores.
Despite this limitation, we found that COXEN prediction was
generally more significantly predictive for the combination
chemotherapy, which, we believe, partially justifies such an
assumption.
Some limitations of this study should be noted. Our grouping of
the validation cases into responders (CR) and non-responders (PR,
SD, PD) were clinically justified because cases with CR had
excellent long-term survival whereas those with PR, SD, PD
patients had a variable outcome. However, most cases with PR
had some degree of tumor response and therefore these cases were
not strictly resistant to therapy even if their long-term benefit from
chemotherapy remained uncertain. To address the impact of this
dichotomization, we may need to correlate prediction scores with
a residual cancer burden treated as a continuous response variable
in a future study. Also, genomic data from patients treated with
single drugs were not available for validation. The lack of data
from patients with different single agent therapies also limits the
ability to truly evaluate the regimen specificity of the cell-line
derived signatures. Our current combination-drug predictor was
mathematically derived from single-drug predictors, assuming
independence of these drugs’ activities. This combination-drug
prediction modeling may be too naı ¨ve to capture the complexity of
potential multi-drug interactions that can occur during treatment
which may also need to be expanded based on a combination of
drug activities on these cell lines.
Several intriguing questions remain: if platinum resistance could
be predicted preoperatively—in the absence of any therapeutic
advancement—would we change surgical management? Would
we change adjuvant or neoadjuvant chemotherapy choices?
Would we be able to individualize cancer care for women with
ovarian cancer? We think these questions can only be explicitly
answered in the setting of a prospective clinical trial. Nevertheless,
the preliminary data presented here suggest that platinum resistant
patients with ovarian cancer can be selectively guided based on
our molecular assays.
All of our microarray and patient data have been submitted to
the GEO web site and will be released upon publication.
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Figure S1 COXEN Biomarkers and Gene Networks for
Carboplatin and Paclitaxel. (A) IPA Network Analysis for
Carboplatin COXEN Biomarkers. (B) Clustering heatmap analysis
with major gene networks with x-axis responder (red) and non-
responder (green) patients and y-axis with Cell cycle network (red),
Cellular growth and prolife ration network (green), and Connec-
tive tissue development and function and other cancer gene
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Figure S2 PPV and NPV Analysis for COXEN Predictors
on UVA-55. Positive predictive value (PPV) and negative
predictive value (NPV) were plotted by varying cutoff
values for predicted responders for: (A) Carboplatin
Predictor, (B) Paclitaxel Predictor, (C) Combination Predictor.
(PDF)
Figure S3 Odds Ratio of Platinum-based Chemotherapy
Response between the Predictive Responders and Pre-
dictive Non-Responders. The odds ratio of chemotherapy
response was 4.5,7.1 times favorable for the predictive respond-
ers both for Dressman-119 and UVA-55 patient sets, with 95% CI
[1.315–38.912] and [1.013–20.096], respectively.
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